• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术后监测对胰腺导管腺癌的临床获益:系统评价和荟萃分析。

Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.

机构信息

Hepatobiliary and Pancreatic Surgery Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom.

Hepatobiliary and Pancreatic Surgery Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom; College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.

出版信息

Eur J Surg Oncol. 2021 Sep;47(9):2248-2255. doi: 10.1016/j.ejso.2021.04.031. Epub 2021 May 10.

DOI:10.1016/j.ejso.2021.04.031
PMID:34034941
Abstract

BACKGROUND

The value of routine surveillance after resection of pancreatic ductal adenocarcinoma (PDAC) is unclear, and expert guidelines offer conflicting recommendations. This study is a systematic review of evidence for surveillance programs.

METHODS

A systematic review of studies evaluating different surveillance methods was undertaken. A meta-analysis was performed for those studies reporting rates of asymptomatic recurrence, treatment of recurrence and overall survival, according to different surveillance methods.

RESULTS

Ten studies were included in the literature review, with five studies appropriate for meta-analysis (1596 patients). Patients within active surveillance programs were more likely to have recurrence detected at an asymptomatic stage (Pooled Rate: 49.3% vs. 19.1%, p = 0.043). Within studies reporting these outcomes, patients with asymptomatic recurrence were more likely to receive treatment for recurrence (Odds Ratio 3.49; 95% CI: 1.73-7.07; p < 0.001) and had longer overall survival (Mean Difference: 9.5 months; 95% CI: 4.1-14.8; p < 0.001) than those with symptoms at time of recurrence.

DISCUSSION

Routine surveillance after surgery for PDAC appears to detect more patients at an asymptomatic stage. Data from these non-randomised trials also suggest that treatment rates and survival may be superior in patients were recurrence is detected when asymptomatic. As such, these data suggest that routine surveillance may improve patient outcomes, although an appropriately conducted trial would be required to address concerns that various sources of bias may be affecting these results.

摘要

背景

胰腺导管腺癌(PDAC)切除术后常规监测的价值尚不清楚,专家指南的建议也存在冲突。本研究对监测方案的证据进行了系统评价。

方法

对评估不同监测方法的研究进行了系统评价。根据不同的监测方法,对报告无症状复发率、复发治疗和总生存率的研究进行了荟萃分析。

结果

文献复习纳入 10 项研究,其中 5 项研究适合荟萃分析(1596 例患者)。主动监测方案中的患者更有可能在无症状阶段发现复发(汇总率:49.3%比 19.1%,p=0.043)。在报告这些结果的研究中,无症状复发患者更有可能接受复发治疗(优势比 3.49;95%可信区间:1.73-7.07;p<0.001),总生存率更长(平均差异:9.5 个月;95%可信区间:4.1-14.8;p<0.001)比复发时出现症状的患者。

讨论

PDAC 手术后常规监测似乎可以更早期地发现更多无症状患者。这些非随机试验的数据还表明,在无症状时发现复发的患者中,治疗率和生存率可能更高。因此,这些数据表明常规监测可能改善患者的预后,但需要进行适当的临床试验,以解决各种偏倚来源可能影响这些结果的担忧。

相似文献

1
Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.术后监测对胰腺导管腺癌的临床获益:系统评价和荟萃分析。
Eur J Surg Oncol. 2021 Sep;47(9):2248-2255. doi: 10.1016/j.ejso.2021.04.031. Epub 2021 May 10.
2
Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design.使用基于复发监测策略的 RADAR-PANC 对胰腺导管腺癌切除术后的疾病复发进行检测:一项按照队列内试验设计的国际随机对照试验方案。
Trials. 2024 Jun 20;25(1):401. doi: 10.1186/s13063-024-08223-5.
3
CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.CA19-9 用于监测胰腺导管腺癌术后情况:预测复发并随时间改变预后。
Ann Surg Oncol. 2018 Nov;25(12):3483-3491. doi: 10.1245/s10434-018-6521-7. Epub 2018 May 21.
4
Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection.血清SPan-1是胰腺癌根治性切除术后早期复发的重要危险因素。
Dig Surg. 2017;34(2):125-132. doi: 10.1159/000449041. Epub 2016 Sep 23.
5
Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.解剖可切除的胰腺导管腺癌中,术前 CA 19-9 与癌症结局无关:一项回顾性队列分析。
J Surg Oncol. 2020 Nov;122(6):1074-1083. doi: 10.1002/jso.26103. Epub 2020 Jul 16.
6
Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.胰腺导管腺癌多学科治疗时代实际长期生存的预后因素。
Langenbecks Arch Surg. 2018 Sep;403(6):693-700. doi: 10.1007/s00423-018-1709-7. Epub 2018 Sep 15.
7
A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.术前复发风险模型可能有助于为接受新辅助治疗的胰导管腺癌患者的初始治疗决策提供依据。
Surgery. 2020 Dec;168(6):1003-1014. doi: 10.1016/j.surg.2020.02.013. Epub 2020 Apr 19.
8
Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer.胰腺癌术前临床生理检查结果的早期复发预测因素
Eur Surg Res. 2018;59(5-6):329-338. doi: 10.1159/000494382. Epub 2018 Nov 19.
9
Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?胰腺导管腺癌切除术后CA19-9恢复正常并不等同于治愈?
Asian Pac J Cancer Prev. 2015;16(2):661-6. doi: 10.7314/apjcp.2015.16.2.661.
10
Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.可解剖切除的早期胰腺癌中糖类抗原19-9升高与总生存期降低独立相关且是新辅助治疗的指征:一项国家癌症数据库研究
J Am Coll Surg. 2016 Jul;223(1):52-65. doi: 10.1016/j.jamcollsurg.2016.02.009. Epub 2016 Feb 23.

引用本文的文献

1
Impact of Structured Postoperative Surveillance on Survival in Patients with Resected Pancreatic Adenocarcinoma.结构化术后监测对切除性胰腺腺癌患者生存的影响
Cancers (Basel). 2025 Apr 24;17(9):1424. doi: 10.3390/cancers17091424.
2
Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma.胰腺腺癌切除术后的常规影像学检查或症状性随访
JAMA Surg. 2025 Jan 1;160(1):74-84. doi: 10.1001/jamasurg.2024.5024.
3
Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design.
使用基于复发监测策略的 RADAR-PANC 对胰腺导管腺癌切除术后的疾病复发进行检测:一项按照队列内试验设计的国际随机对照试验方案。
Trials. 2024 Jun 20;25(1):401. doi: 10.1186/s13063-024-08223-5.
4
Imaging of pancreatic ductal adenocarcinoma - An update for all stages of patient management.胰腺导管腺癌的影像学检查——患者管理各阶段的最新进展
Eur J Radiol Open. 2024 Feb 8;12:100553. doi: 10.1016/j.ejro.2024.100553. eCollection 2024 Jun.
5
Detection of asymptomatic recurrence following curative surgery improves survival in patients with gastric cancer: A systematic review and meta-analysis.胃癌根治性手术后无症状复发的检测可提高患者生存率:一项系统评价与荟萃分析
Front Oncol. 2022 Oct 26;12:1011683. doi: 10.3389/fonc.2022.1011683. eCollection 2022.